Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03844360
PHASE4

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Sponsor: Wei Zhao

View on ClinicalTrials.gov

Summary

The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.

Key Details

Gender

All

Age Range

1 Day - 18 Years

Study Type

INTERVENTIONAL

Enrollment

1500

Start Date

2016-01-31

Completion Date

2026-12-31

Last Updated

2025-03-30

Healthy Volunteers

No

Interventions

DRUG

Bortezomib

bortezomib was administered follow the doctor's advice.

DRUG

Eltrombopag

eltrombopag was administered follow the doctor's advice.

DRUG

Imatinib

imatinib was administered follow the doctor's advice.

DRUG

dasatinib

dasatinib was administered follow the doctor's advice.

DRUG

Pegaspargase

pegaspargase was administered follow the doctor's advice.

DRUG

Anti-Infective Drugs

anti-infective drugs was administered follow the doctor's advice.

DRUG

PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor

pegaspargase was administered follow the doctor's advice.

Locations (2)

Department of Pediatrics, the Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China

State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Tanjin, Tianjin Municipality, China